Tesofensine vs Semaglutide
Triple monoamine reuptake inhibitor vs GLP-1 receptor agonist — two fundamentally different approaches to weight management research.
Last updated: 2026-03-08
Quick Comparison Table
| Category | Tesofensine | Semaglutide |
|---|---|---|
| Drug Class | Triple monoamine reuptake inhibitor | GLP-1 receptor agonist |
| Primary Mechanism | Inhibits dopamine, serotonin, noradrenaline reuptake | Activates GLP-1 receptors in gut and brain |
| Administration | Oral tablet (daily) | Subcutaneous injection (weekly) |
| Weight Loss (Trials) | ~12.8% at 0.5mg over 24 weeks | ~15-17% at 2.4mg over 68 weeks |
| Approval Status | Phase III (not yet approved) | FDA/EMA approved (Wegovy/Ozempic) |
| Effect on Appetite | Reduces appetite via central monoamine pathways | Reduces appetite via GLP-1 signalling and gastric slowing |
| Cardiovascular Effects | Increased heart rate observed in trials | Proven cardiovascular risk reduction (SELECT trial) |
| Key Safety Concern | CNS stimulation, insomnia, elevated heart rate | GI side effects (nausea, vomiting), pancreatitis risk |
Mechanism of Action
Tesofensine
Tesofensine Mechanism:
Tesofensine is a triple monoamine reuptake inhibitor that blocks the reuptake of three key neurotransmitters:
1. **Dopamine** — Enhances reward signalling, reducing food-seeking behaviour 2. **Serotonin (5-HT)** — Increases satiety signalling, reducing appetite 3. **Noradrenaline** — Increases sympathetic tone and thermogenesis
Originally developed for Alzheimer's and Parkinson's disease, weight loss was observed as a consistent side effect. Its mechanism is purely central — acting on hypothalamic appetite centres and mesolimbic reward pathways.
Unlike amphetamine-based stimulants, Tesofensine does not cause direct monoamine release, only reuptake inhibition. This is thought to reduce abuse potential, though it has not been fully characterised.
Semaglutide
Semaglutide Mechanism:
Semaglutide is a GLP-1 receptor agonist — a modified version of the native incretin hormone GLP-1 with a 165-hour half-life enabling weekly dosing.
Key pathways: 1. **Hypothalamic appetite suppression** — GLP-1 receptors in the arcuate nucleus reduce hunger 2. **Delayed gastric emptying** — Slows food transit, increasing satiety 3. **Pancreatic insulin secretion** — Glucose-dependent insulin release 4. **Hepatic glucose output reduction** — Reduces gluconeogenesis
Semaglutide's weight loss is driven primarily by appetite reduction (~80%) and modestly by delayed gastric emptying. It does not directly affect monoamine signalling.
The SELECT trial (17,604 patients, 4 years) demonstrated a 20% reduction in major cardiovascular events — establishing Semaglutide as the first obesity drug with proven cardioprotective benefits.
Clinical Trial Evidence
Tesofensine Clinical Studies
Participants: 203
Duration: 24 weeks
12.8% weight loss at 0.5mg vs 2.0% placebo; dose-dependent appetite reduction.
Statistically significant
Participants: 140
Duration: 48 weeks
Sustained weight loss of ~10.6% at 0.5mg over 48 weeks with maintained appetite suppression.
Statistically significant
Participants: 549
Duration: 14 weeks
Mean weight loss of 4% observed as side effect in AD study; appetite suppression noted across all dose groups.
Not statistically significant
Participants: 203
Duration: 24 weeks
Mean heart rate increase of 7.4 bpm at 0.5mg; modest systolic BP increase of 1-2 mmHg. No serious cardiovascular events.
Not statistically significant
Participants: 203
Duration: 24 weeks
Significant improvements in waist circumference, fasting insulin, triglycerides, and adiponectin at 0.5mg dose.
Statistically significant
Semaglutide Clinical Studies
Participants: 1961
Duration: 68 weeks
Mean weight loss of 14.9% with Semaglutide 2.4mg vs 2.4% with placebo. One-third of participants achieved ≥20% weight loss.
Statistically significant
Participants: 1210
Duration: 68 weeks
Mean weight loss of 9.6% in T2DM patients with 2.4mg dose vs 3.4% placebo. HbA1c reduction of 1.6%.
Statistically significant
Participants: 17604
Duration: 4 years
20% reduction in MACE (major adverse cardiovascular events). First obesity drug to demonstrate cardiovascular mortality benefit.
Statistically significant
Participants: 304
Duration: 104 weeks
Sustained weight loss of 15.2% at 2 years. Weight regain noted upon discontinuation in extension studies.
Statistically significant
Participants: 3297
Duration: 2.1 years
26% reduction in MACE in type 2 diabetes patients. Non-fatal stroke reduced by 39%.
Statistically significant
Benefits Comparison
Tesofensine Unique Benefits
- Rapid early weight loss (~5% in 4 weeks)
- Oral administration (no injection needed)
- Potential dual benefit for appetite and mood via dopamine
- Thermogenic effect from noradrenergic activity
- Dose-dependent and predictable weight loss
Shared Benefits
- Significant appetite suppression
- Improvements in metabolic biomarkers
- Reduction in waist circumference
- Dose-dependent efficacy
Semaglutide Unique Benefits
- Superior long-term weight loss (15-17% over 68 weeks)
- Proven cardiovascular mortality reduction
- Weekly injection convenience
- Glycaemic control in type 2 diabetes
- Extensive real-world safety data (100M+ prescriptions)
Research & Evidence
Tesofensine Research
Tesofensine's research base is relatively small. The TIPO Phase II studies (203 patients, 24-48 weeks) showed impressive weight loss but raised cardiovascular safety questions. The drug is currently in Phase III development under the brand name Tesomet (Tesofensine + Metoprolol combination to counteract heart rate increases). No large-scale cardiovascular outcomes trial has been conducted.
Semaglutide Research
Semaglutide has one of the most extensive evidence bases of any obesity drug — the STEP programme (4,500+ patients), SUSTAIN programme for diabetes (8,000+ patients), and the landmark SELECT cardiovascular outcomes trial (17,604 patients, 4 years). Real-world data from 100M+ prescriptions globally provides additional safety confidence.
Head-to-Head Analysis
Direct Comparison:
No head-to-head trial has compared Tesofensine and Semaglutide directly.
Efficacy: Semaglutide at 2.4mg weekly produced ~15-17% weight loss over 68 weeks (STEP trials). Tesofensine at 0.5mg daily produced ~12.8% weight loss over 24 weeks (Phase II). The shorter trial duration for Tesofensine makes direct comparison difficult, but early weight loss kinetics appear competitive.
Mechanism Complementarity: These two drugs act through entirely non-overlapping pathways — central monoamine modulation vs peripheral incretin signalling. This has generated research interest in potential combination therapy.
Safety Profile: Semaglutide has a well-characterised safety profile from 17,000+ patient cardiovascular outcomes data. Tesofensine's safety database is much smaller, with cardiovascular concerns (elevated heart rate, blood pressure) being the primary regulatory hurdle.
Protocol Comparison
Tesofensine Protocol
Tesofensine Theoretical Protocols (Research-Based):
Dosing: Phase II trials used 0.25mg, 0.5mg, and 1.0mg orally once daily. 0.5mg showed the optimal efficacy/safety balance.
Routes: - Oral tablet only
Duration: Studies ran 24-48 weeks. Optimal duration not established.
Key Consideration: The Tesomet combination (Tesofensine + Metoprolol) aims to mitigate the heart rate increase seen with Tesofensine alone.
⚠️ Disclaimer: Tesofensine is not approved for clinical use in any jurisdiction.
Semaglutide Protocol
Semaglutide Therapeutic Protocols (Approved):
Dosing (Obesity — Wegovy): Titration schedule over 16 weeks: 0.25mg → 0.5mg → 1.0mg → 1.7mg → 2.4mg weekly.
Dosing (T2DM — Ozempic): Start 0.25mg weekly for 4 weeks, then 0.5mg. May increase to 1.0mg or 2.0mg.
Routes: - Subcutaneous injection (abdomen, thigh, upper arm) — weekly
Duration: Long-term/indefinite for chronic weight management. Weight regain occurs upon discontinuation.
⚠️ Note: Prescription medication requiring qualified medical supervision.
Safety Profiles
Tesofensine Safety
Tesofensine Safety Profile (Phase II Data):
Common side effects: dry mouth (34%), nausea (22%), constipation (19%), insomnia (17%), increased heart rate (mean +7.4 bpm at 0.5mg).
Primary concerns: - Cardiovascular: Dose-dependent heart rate increase; modest BP elevation - CNS: Insomnia, anxiety at higher doses - Psychiatric: Theoretical risk of mood disturbance (monoamine modulation)
The 1.0mg dose was dropped due to unfavourable cardiovascular profile. The Tesomet combination with Metoprolol was developed specifically to address heart rate concerns.
No large-scale safety database exists. Phase III trials are ongoing.
Semaglutide Safety
Semaglutide Safety Profile (Extensive Data):
Common side effects: nausea (44%), diarrhoea (30%), vomiting (24%), constipation (24%) — most transient during titration.
Serious but rare: pancreatitis (<0.3%), gallbladder events, thyroid C-cell concerns (rodent only, not confirmed in humans).
Cardiovascular: SELECT trial demonstrated 20% MACE reduction — actively cardioprotective.
Contraindications: Personal/family history of medullary thyroid carcinoma, MEN2 syndrome.
Post-marketing (100M+ prescriptions): No unexpected safety signals. GI side effects manageable with proper titration.
The Verdict
Semaglutide is the established standard-of-care with an unmatched evidence base — proven cardiovascular benefit, regulatory approval, and extensive real-world data. Tesofensine is a promising investigational compound with competitive early weight loss data and the significant advantage of oral dosing, but it lacks the large-scale safety evidence and regulatory approval of Semaglutide. Their non-overlapping mechanisms make them conceptually interesting as potential combination candidates. For clinicians and researchers today, Semaglutide represents the validated choice; Tesofensine represents the future potential.
Frequently Asked Questions
Conclusion
Tesofensine and Semaglutide represent two fundamentally different pharmacological approaches to obesity. Semaglutide, as an approved GLP-1 agonist with proven cardiovascular benefit and 100M+ prescriptions of real-world data, is the current gold standard. Tesofensine, a central monoamine reuptake inhibitor with competitive early weight loss results and oral convenience, remains investigational with outstanding cardiovascular safety questions. Their distinct mechanisms offer complementary pathways that may prove valuable in combination research. Both are potent therapeutic agents requiring medical supervision.
Medical Disclaimer
The information provided in this comparison is for educational and research purposes only. Neither Tesofensine nor Semaglutide is approved for human therapeutic use by the MHRA, EMA, or FDA. This content does not constitute medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement.